Hepatitis C Virus (HCV) infection poses a huge burden
worldwide, as well as on the Bangladeshis, being a
leading cause of all forms of chronic liver diseases next
only to HBV1,2. A recent study in Bangladesh showed a
prevalence of 0.88%, though figures vary due to lack of
representative population study in Bangladesh2. The
advent of new generation oral antiviral therapy has led
to major improvements in efficacy and tolerability but
has also resulted in an explosion of data with increased
treatment choice complexity. The questions of who
should be treated and with what regimen, will be
increasingly complex to address and will require careful
consideration. As therapy improves, identification and
care of patients who need treatment will be the next
challenge3. We need to update ourselves continuously
to provide optimum treatment to our patients.